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Abstract
TDP-43 (encoded by the gene TARDBP) is an RNA binding protein
central to the pathogenesis of amyotrophic lateral sclerosis
(ALS). However, how TARDBP mutations trigger pathogenesis
remains unknown. Here, we use novel mouse mutants carrying
point mutations in endogenous Tardbp to dissect TDP-43 func-
tion at physiological levels both in vitro and in vivo. Interest-
ingly, we find that mutations within the C-terminal domain of
TDP-43 lead to a gain of splicing function. Using two different
strains, we are able to separate TDP-43 loss- and gain-of-func-
tion effects. TDP-43 gain-of-function effects in these mice reveal
a novel category of splicing events controlled by TDP-43, referred
to as “skiptic” exons, in which skipping of constitutive exons
causes changes in gene expression. In vivo, this gain-of-function
mutation in endogenous Tardbp causes an adult-onset
neuromuscular phenotype accompanied by motor neuron loss
and neurodegenerative changes. Furthermore, we have validated
the splicing gain-of-function and skiptic exons in ALS patient-
derived cells. Our findings provide a novel pathogenic mecha-
nism and highlight how TDP-43 gain of function and loss of
function affect RNA processing differently, suggesting they may
act at different disease stages.
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Introduction
TDP-43 is a ubiquitously expressed, predominantly nuclear, RNA
binding protein, which is involved in multiple steps of RNA process-
ing and maturation, including transcription and splicing (Ratti &
Buratti, 2016; Ederle & Dormann, 2017). TDP-43 has two RNA bind-
ing domains (RRM1 and RRM2) and a C-terminal low complexity
glycine-rich domain (LCD), in which mutations causative for amyo-
trophic lateral sclerosis (ALS) are clustered (Ratti & Buratti, 2016;
Ederle & Dormann, 2017).
Mutations in TARDBP account for a small percentage (< 5%) of
ALS cases; however, cytoplasmic TDP-43 inclusions, accompanied
by nuclear depletion of the protein, are the key pathological hall-
mark of > 98% of ALS indicating the profound importance of TDP-
43 in pathogenesis (Mackenzie et al, 2010; Sreedharan et al, 2008);
furthermore, TDP-43 deposition has been consistently described in a
range of other neurodegenerative diseases most prominently
frontotemporal dementia (Neumann et al, 2006).
Despite this, the mechanism(s) by which TDP-43 mutations lead
to disease remains unknown, and both nuclear loss of function
(LOF) and cytoplasmic gain of function (GOF) have been proposed
to play a role (Ling et al, 2013). TDP-43 deposition and nuclear
depletion in post-mortem tissue support a potential role for LOF in
end-stage ALS. However, little is known about the early-stage effects
of TARDBP mutations, including the impact on RNA metabolism
(Koyama et al, 2016).
TDP-43 is extremely dosage sensitive and is tightly autoregulated
by a mechanism that involves TDP-43 protein binding to its own
30UTR; these properties have proven challenging for studying
the effects of TARDBP mutations in vivo (Ayala et al, 2011;
Polymenidou et al, 2011; Avendan˜o-Va´zquez et al, 2012). Thus, the
main approach to studying LOF, by using null mice, has been
hampered because TDP-43 knockout (KO) causes very early embry-
onic lethality, and heterozygous mice have normal levels of TDP-43
due to autoregulation (Kraemer et al, 2010; Sephton et al, 2010; Wu
et al, 2010; Ricketts et al, 2014). However, conditional KO strategies
and downregulation of TDP-43 via siRNA suggest that acute TDP-43
loss of function could lead to neurodegeneration (Chiang et al,
2010; Wu et al, 2012; Iguchi et al, 2013; Yang et al, 2014).
Similarly, in transgenic mice, even low levels of overexpression
of wild-type (WT) or mutant TDP-43 cause multiple RNA changes,
making it difficult to identify the pathogenic RNA profile that occurs
physiologically in disease (Arnold et al, 2013).
Here, we have addressed these issues by working with animals
from an allelic series carrying point mutations within mouse
endogenous Tardbp to dissect the molecular effects of TDP-43 LOF
and GOF in vivo in a physiological setting and in the absence of the
confounding effects of ectopically expressed transgenes. One of our
novel mouse mutants has decreased TDP-43 RNA binding capacity,
which allowed us to characterise TDP-43 LOF. A second strain
carries a mutation within the C-terminal low complexity glycine-rich
domain (LCD) of TDP-43, which induces a splicing GOF. The analy-
sis of this GOF uncovered entirely novel splicing events in genes not
known to be controlled by TDP-43, such that a set of constitutive
exons—here named “skiptic exons” (SE)—are skipped due to TDP-
43 GOF.
Remarkably, the skipping of constitutive exons induced by GOF
is in contrast to the previously identified TDP-43 LOF-induced
cryptic exons, which are normally repressed but in LOF are aber-
rantly included in mRNAs (Ling et al, 2015; Humphrey et al, 2017).
Furthermore, and importantly for modelling of TDP-43 disease
processes, our LCD mutant mouse strain with a GOF develops a
progressive neuromuscular phenotype, in the absence of LOF
changes, thus showing that GOF is sufficient to initiate pathogene-
sis. Lastly, we show that splicing GOF and SEs occur also in another
C-terminal ALS-causative Tardbp mutation and in fibroblasts
derived from ALS patients carrying TARDBP mutations.
Our results shed light on novel aspects of TDP-43 biology and
provide powerful new tools to gain insight into the early stages of
TDP-43 neurodegeneration in vivo.
Results
Novel endogenous missense mutations in TDP-43 RRM2 and LCD
To study the effects of mutations in different domains of TDP-43
in vivo, at physiological levels, we selected two endogenous Tardbp
mutations from a mouse allelic series found by screening muta-
genised DNA archives from two large N-ethyl-N-nitrosourea (ENU)
mouse mutagenesis programmes (Acevedo-Arozena et al, 2008;
Gondo et al, 2010). The first mutation (F210I) is located in the
important RNA recognition motif 2 (RRM2) of TDP-43; hence, we
refer to this mutation as RRM2mut hereafter (Fig 1A).
The second mutation results in an M323K change in TDP-43 and
falls within the C-terminal LCD where almost all known ALS-
causing mutations are clustered—specifically within a 20 amino
acid stretch that influences TDP-43 alpha-helix structure which
is important for liquid phase separation, aggregation and protein
self-interaction (Conicella et al, 2016). Importantly, we found in
an in vitro turbidity assay that the M323K mutation containing
C-terminal domain decreased the propensity for phase separation
compared to wild type—similarly to the human ALS-causing muta-
tion TDP-43 Q331K (Appendix Fig S1). Hereafter, we refer the M323K
mutation strain as LCDmut (Fig 1A).
To generate cohorts of animals for in vivo analysis, we produced
founder mice from the ENU programmes’ sperm archives and gener-
ated litters by in vitro fertilisation; F1 mice were then backcrossed
for at least five generations to eliminate non-linked ENU mutations
and to place the mutations on congenic inbred backgrounds. We
found both mutations, RRM2mut and LCDmut, were embryonic
lethal on a congenic C57BL/6J background, supporting a significant
impact of both amino acid changes on TDP-43 function
(Appendix Table S1).
Genetic background effects can profoundly modify phenotype,
and there are several reports in the literature of different back-
grounds, or combinations of backgrounds, rescuing embryonic
lethality (LeCouter et al, 1998). To determine whether we could
produce homozygous animals by changing genetic background, we
undertook a standard mouse genetics approach and backcrossed
both RRM2mut and LCDmut lines onto C57BL/6J and onto DBA/2J
for at least five generations and then worked with F1 C57BL/6J-
DBA/2J intercrosses to produce homozygotes. We found the RRM2-
mut allele remained homozygous embryonic lethal and no live mice
were detected. However, LCDmut homozygous mice were viable in
this mixed genetic background (Appendix Table S1).
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RRM2mut and LCDmut cause splicing LOF and GOF, respectively
To investigate the effects of these TDP-43 mutations on splicing in
an endogenous physiological context, we performed the CFTR mini-
gene assay in mouse embryonic fibroblasts (MEFs). RRM2mut
caused a highly significant shift towards exon inclusion, similar to
the well-documented effect of TDP-43 knockdown (Appendix Fig
S2), showing a dose-dependent LOF (Fig 1B). Surprisingly, the
LCDmut showed an opposite effect, leading to an increase in exon
exclusion, suggesting GOF (Fig 1B).
We then investigated by RT–PCR whether a similar effect was
present in a well-characterised endogenous TDP-43 splicing target,
exon 18 of Sortilin 1. Exon 18 inclusion was increased in RRM2mut,
as previously described in TDP-43 knockdown (Polymenidou et al,
2011), but had an opposite change in LCDmut, further supporting
the splicing GOF (Fig 1C).
A
B
C
D
E
F
Figure 1. Novel endogenous mutations RRM2mut and LCDmut have a loss- and gain-of-function effect on splicing.
A Diagram of TDP-43 illustrates the location of non-synonymous mutations used in this study.
B Agarose gel and quantification of CFTR minigene splicing assay performed on MEFs from RRM2mut and LCDmut homozygous (HOM), heterozygous (HET) and
littermate (WT) controls show an increase in exon inclusion in RRM2mut and a decrease in LCDmut. RRM2mut ANOVA P < 0.0001; LCDmut ANOVA P = 0.0166;
Bonferroni multiple comparison tests are plotted as: *P < 0.05; **P < 0.01; ***P < 0.001; mean and SEM plotted; N = 3 per genotype.
C Quantification of Sortilin 1 RT–PCR products from RRM2mut and LCDmut MEFs shows exon 18 inclusion increases in RRM2mut and decreases in LCDmut.
RRM2mut and LCDmut ANOVA P < 0.0001; Bonferroni multiple comparison tests are plotted as: **P < 0.01; ***P < 0.001; mean and SEM plotted; N = 3 per
genotype.
D EMSA assay performed with increasing quantities of recombinant WT and RRM2mut TDP-43 with radiolabelled (UG)6 RNA and TDPBR RNA shows reduced RNA
binding of recombinant RRM2mut.
E Scatter plot of pentamer enrichment in TDP-43 iCLIP shows a canonical TDP-43 pattern of enrichment in TG/GT-containing pentamers in RRM2mut (left) and LCDmut
(right) along with littermate WT controls.
F Mapping of TDP-43 binding sites in RRM2mut (left) and LCDmut (right) along with littermate WT controls iCLIP datasets shows a similar distribution genome-wide.
Source data are available online for this figure.
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Since TDP-43 protein levels appeared to be unchanged in both
lines in MEFs (Appendix Fig S3), we performed electromobility
shift assays (EMSA) to evaluate the RNA binding capacity of WT,
RRM2mut and LCDmut recombinant TDP-43 (Buratti & Baralle,
2001). RNA binding was reduced in RRM2mut TDP-43, whereas it
was unchanged with the LCDmut mutation (Fig 1D and
Appendix Fig S4).
To address whether the reduced RNA binding capacity in the
RRM2mut was associated with changes in RNA binding specificity,
we performed TDP-43 iCLIP (Tollervey et al, 2011) on CNS tissue.
As RRM2mut homozygotes are not viable, we performed iCLIP in
embryonic brains for that strain. However, as homozygous LCDmut
are viable on a hybrid background, we were able to perform iCLIP
on adult brain—the most relevant age for the effects of the TDP-43
mutation. The iCLIP data cannot be used to draw quantitative
binding conclusions, but in each case, the binding motifs and
transcriptome-wide distribution of RRM2mut and LCDmut TDP-43
binding sites within exons, introns, UTRs and intergenic regions
showed no changes from wild-type TDP-43 (Fig 1E and F). Thus,
RRM2mut is a hypomorphic allele, as it shows reduced RNA binding
affinity whilst maintaining the typical TDP-43 sequence recognition
and leads to a splicing loss of function. LCDmut instead induces a
splicing gain of function whilst maintaining normal RNA binding
capacity and specificity.
RRM2mut and LCDmut show opposing effects transcriptome-
wide and counteracting biological effects
We next sought to directly compare our two mutants to a bona fide
TDP-43 LOF. We could not use TDP-43 null mice as they die before
E6.5, so we performed RNA-seq on MEFs homozygous for the
RRM2mut and the LCDmut alleles comparing them each to their
wild-type controls, in parallel with wild-type MEFs in which we
induced TDP-43 knockdown with shRNA (Tardbp-shRNA) compar-
ing them to scramble sequence shRNA (Appendix Fig S5). Two-way
comparisons showed that RRM2mut aligns with Tardbp-shRNA,
with all significantly differentially expressed exons in both datasets
up- or downregulated in agreement. Conversely and strikingly,
LCDmut showed all of the significant differentially expressed exons
changing in the opposing direction to RRM2mut and to Tardbp-
shRNA (Fig 2A, Appendix Table S2).
These analyses identified splicing targets that are affected in
opposing directions by RRM2mut and LCDmut, along with unique
splicing events that occur within each mutant. To investigate these
effects further, we crossed the two mutant lines, on a C57BL/6J
background, and generated compound heterozygotes. Whilst RRM2-
mut and LCDmut are both homozygous lethal in this background
and produced 52 and 400 splicing changes, and 883 and 34 expres-
sion changes respectively, the compound heterozygous RRM2/
LCDmut mice were viable (although 8.8% of the mice instead of the
25% expected by Mendelian ratios, pointing to an incomplete
rescue) and remarkably had only one significant splicing change
and eight differentially expressed genes (FDR < 0.05)—indicating
that RRM2mut LOF and LCDmut GOF complement each other and
that the combination of mutations results in viable animals (Fig 2B
and C).
Overall these results show that the two mutations have
opposing LOF/GOF effects on splicing, providing a novel
mammalian system to specifically assess the role of TDP-43 LOF/
GOF in vivo.
TDP-43 LCD mutations cause novel splicing events, the skipping
of constitutive exons: skiptic exons
Given the relevance of LCD mutations to ALS, we focused our molec-
ular analysis on adult spinal cord RNA-seq from 1-year-old LCDmut
mice; we found 523 significantly differentially spliced events
compared to WT littermate controls. Differential splicing events were
not biased towards lowly expressed genes (Appendix Fig S6). When
we analysed the distribution of splicing changes between the splicing
event categories of cassette exons, retained introns, alternate 30 and
50 junctions, alternate first and last exons, and mutually exclusive
exons, alterations in cassette exons were the most frequent events
(46%; Fig EV1A), with a notably strong preference towards exon
skipping events (in 79% of cassette exons; Fig EV1B). Motif enrich-
ment analysis within 100 bp of each cassette exon:intron boundary
identified the TDP-43 binding motif, UGUGUG, only for exon exclu-
sion (P = 5.2E-28; Fig EV1C). Therefore, exon skipping is associated
with TDP-43 direct RNA binding in LCDmut (Fig EV1G and H). This
is in stark contrast to what we found in RNA-seq from our RRM2mut
LOF line, where, consistent with previously published TDP-43 LOF
datasets, the exon inclusion events have a stronger association with
the UGUGUG TDP-43 binding motif (Fig EV1D–F).
We further analysed the skewed preference in LCDmut for exon
skipping and identified a novel previously unreported effect: the
skipping of otherwise constitutively expressed exons. We termed
these novel events skiptic exons (SEs) and to define them we used
the following per cent spliced in (PSI) criteria—exons that were
included in WT (PSI > 0.95) and skipped in mutants (ΔPSI decrease
of > 0.05).
We identified 47 SEs in 44 genes in our LCDmut RNA-seq data
and validated 7 with RT–PCR. Mean and median PSI of these
events in wild-type littermates were 0.98 and 0.99, mean and
median ΔPSI in LCDmut were 0.12 and 0.09, and LCDmut
exon exclusion mean and median fold-changes were 17.6 and 8.6,
respectively (Fig 3A and C, Appendix Table S3). Crucially, SEs
found in LCDmut are absent in RRM2mut, as exemplified by
Herc2 sashimi plots (Fig 3B), with the exception of one in Tsn,
which is present also in compound heterozygous RRM2mut/
LCDmut samples. To exclude possible random sampling effects,
we performed splicing analysis on 50 random sample permuta-
tions showing that the identification of SEs is not due to random
effects (Appendix Table S4 and Appendix Fig S7).
Intriguingly, SEs represent the opposite phenomenon to recently
described cryptic exons (CEs), in which TDP-43 LOF induces the
inclusion of otherwise constitutively repressed exons (Ling et al,
2015; Humphrey et al, 2017). We defined cryptic exons (CEs) as
exons that are significantly de-repressed using the reverse criteria
from the above skiptic exons: repressed in WT (PSI < 0.05) and
present in mutants (ΔPSI of > 0.05). We identified 33 CEs in the
RRM2mut line and validated them by RT–PCR, but only three in the
LCDmut (Figs 3A and EV2A and C). CEs identified in RRM2mut, with
the exception of one event in Reep3, are absent in LCDmut, as exem-
plified by sashimi plots of Adnp2 (Fig EV2B). Interestingly, Reep3 CE
is present also in our RRM2mut/LCDmut compound heterozygotes,
suggesting a possible distinct mechanism for this event.
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Overall these results show that, whilst LOF and GOF act in
opposing direction on a shared pool of alternatively spliced exons,
GOF acts on a distinct set of genes inducing the skipping of constitu-
tive exons (SEs) and LOF affects a separate set of genes where it
induces the inclusion of CEs (Fig 4).
Skiptic exons are linked to direct TDP-43 RNA binding
To determine whether TDP-43 RNA binding is associated with SEs,
we used the combination of RNA-seq and iCLIP data. RNA maps
show an enrichment of TDP-43 binding sites within SEs, and in their
downstream introns, and this pattern parallels that of CEs in RRM2-
mut (Fig 5A and B). Appendix Table S5 illustrates how TDP-43
binding to SEs (66.0%) is enriched compared to other differentially
alternatively spliced exons (18.8%), alternatively spliced exons
(6.4%), constitutive exons (7.4%) and all GENCODE mouse exons
(5%). The similarity of TDP-43 binding pattern distribution around
SEs induced by GOF and CEs induced by LOF illustrates how these
binding sites play a role in regulating exon inclusion/exclusion and
strongly support a direct role for TDP-43 RNA binding in these novel
GOF events.
SEs are highly conserved and lead to impaired transcript levels
To further characterise the SEs, we investigated their conserva-
tion, and interestingly, in contrast to CEs, conservation of SEs is
high between species (Fig 5C). We also found that the novel skip-
ping events produced by the LCDmut lead to frameshift or prema-
ture termination codons (PTC) in 15/48 transcripts, resulting in
likely unstable transcripts. Therefore, we compared expression of
transcripts containing SEs to transcripts carrying other differen-
tially regulated cassette exons, and all other transcripts expressed
at similar levels in our RNA-seq dataset; we found the transcripts
that included SEs were significantly more downregulated
(Fig 5D).
Furthermore, the proportion of predicted unstable transcripts
significantly increases (P < 0.05) from 18% in SEs showing no
expression change to 54% in significantly downregulated SEs
C
A
B
Figure 2. TDP-43 RRM2mut and LCDmut show opposing effects transcriptome-wide and counteracting biological effects.
A Two-way comparisons of MEF single exon differential expression changes between RRM2mut, LCDmut and TDP-43 knockdown (KD). N = 3 for each RNA-seq
condition. Z-scores for single exons are plotted (significantly changed exons—FDR < 0.1, DEXSeq—in both datasets are highlighted in red and defined in
Appendix Table S2).
B Diagram illustrating the RRM2mut and LCDmut intercross, with differentially spliced exons (DSE, FDR < 0.01, DEXSeq; N = 3 for each RNA-seq genotype), differentially
expressed genes (DEG, FDR < 0.05, DESeq2) and significant increase in survival of compound heterozygous (P < 0.05). N, numbers of animals produced per genotype;
%, percentage of mice observed per genotype; expected %, percentage of mice expected per genotype.
C Sashimi plots illustrate the unchanged Eif4h splicing in compound heterozygous mice compared to opposing altered splicing in LCDmut and RRM2mut. PSI
determined by SGSeq are plotted.
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(Fig 5E). These results show that SEs have an impact on expression
levels in vivo.
LCDmut induces a progressive neuromuscular phenotype and
affects autoregulation of Tardbp mRNA
To investigate the physiological effect of our LCD mutation, we aged
wild-type, heterozygous and homozygous littermates up to
24 months and found a progressive grip strength deficit in homozy-
gous LCDmut male and female mice after 12 months of age (Fig 6A
and Appendix Fig S8). We analysed in vivo muscle force and found
a significant 38% reduction in homozygous LCDmut mouse tetanic
strength in tibialis anterior muscles at 24 months of age (Fig 6B). We
performed a physiological analysis of motor unit survival (MUNE) to
estimate motor units innervating the extensor digitorum (EDL) muscle
at 24 months. We found a significant 15% reduction in homozygous
LCDmut motor units compared to littermate controls (Fig 6C), show-
ing that LCDmut mice develop a progressive motor dysfunction.
Importantly, motor neuron (MN) counts performed on the sciatic MN
pool at L4–L5 showed a 28% reduction in homozygous LCDmut when
compared to littermate controls (P < 0.05; Fig 6D).
Immunohistochemistry investigations of the spinal cord at
18 months of age showed that homozygous LCDmut mice develop
widespread p62- and ubiquitin-positive inclusions in the ventral
C
A B
Figure 3. Skiptic exons—novel splicing events induced by TDP-43 GOF.
A Volcano plot of LCDmut RNA-seq shows significantly alternatively spliced exons that have either a PSI of < 0.05 and a ΔPSI of > 0.1 (CE, red) or a PSI of > 0.95 and a
DPSI of < 0.1 (SE, blue).
B Sashimi plots show presence of a SE in Herc2 in LCDmut, absent in RRM2mut and WT controls.
C Diagram illustrating SEs (top), representative lanes for acrylamide capillary traces (middle), and quantification (bottom) of RT–PCR (n = 4) validations for seven SEs. T-
test: Ankrd42 P = 9.286e-7; Herc2 P = 0.001269; Pacrgl P = 0.001487; Pex16 P = 3.29e-5; Plod1 = 9.66e-5; Slc6a6 P = 2.077e-5; Ube3c P = 0.000263. Plotted P-value:
**P < 0.01; ***P < 0.001. Mean and SEM plotted.
Source data are available online for this figure.
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regions (Fig 6E and Appendix Fig S8), a hallmark of neurodegenera-
tion. We investigated whether this phenomenon was widespread in
the CNS, and brain immunohistochemistry showed an increase in
p62 pathology in LCDmut brainstem motor nuclei, whilst no change
was detectable in other brain regions including the hippocampus
(Appendix Fig S8). Intriguingly, although p62 inclusions are prefer-
entially enriched in areas where MN is located (spinal cord ventral
horns and brainstem motor nuclei), they do not appear to be loca-
lised to the cytoplasm of MN cell bodies.
We then investigated TDP-43 expression and whether TDP-43
was mislocalised and aggregated in the spinal cord. Surprisingly, we
found Tardbp mRNA levels were significantly upregulated in a
dose-dependent manner in heterozygous and homozygous LCDmut
adult spinal cord (Fig EV3A) and this was consistent with changes
in the well-described TDP-43 autoregulation mechanism, in which
splicing of the Tardbp 30UTR intron 7 (Appendix Fig S9) leads to a
decrease in Tardbp levels. Tardbp intron 7 retention was signifi-
cantly increased in a dose-dependent manner in heterozygous and
homozygous LCDmut (Fig EV3B). Interestingly, the upregulation
and autoregulation changes were also present at embryonic stage
showing how these are induced by the presence of the mutation and
are not a consequence of the neurodegenerative process. However,
TDP-43 protein levels were not significantly changed (Fig EV3C)
and immunohistochemistry showed the absence of TDP-43 cyto-
plasmic inclusions and no nuclear depletion (Appendix Fig S8).
Of note, we also aged RRM2mut heterozygous animals up to
2 years and did not detect any of the above motor phenotypes or
p62 pathology.
In summary, LCDmut gives rise to a progressive neuromuscular
phenotype in vivo. The lack of nuclear depletion suggests that TDP-43
LOF is dispensable for initiation and development of this neuro-
muscular phenotype in LCDmut mice. Indeed, typical molecular
LOF features, such as CEs and downregulation of long introns
(Polymenidou et al, 2011), are absent in LCDmut mice (Figs EV2 and
EV4).
Thus, LCDMut GOF, in the absence of TDP-43 aggregation,
mislocalization and LOF, can directly lead to neurodegenerative
phenotypes when expressed at physiological levels, suggesting
TDP43 GOF plays a key role in driving TDP-43-related ALS.
Splicing GOF and skiptic exons are found in a novel ALS-causative
TDP-43 Q331K knock-in mouse model and in patient-derived cells
LCDmut is located in the hotspot for ALS-causing mutations and
shares similarities in vitro with human pathogenic mutations;
however, as the M323K mutation has not been described in humans
Alternatively spliced exonsConstitutively repressed exons Constitutively included exons
Skiptic exonsCryptic exons
Strong repression effect
Reduction of  repression activity
resulting in novel events
Inhibition of exon inclusion
resulting in splicing modulation No repression effect
Altered modulation
of alternative splicing
Altered modulation
of alternative splicing
Increase of repression activity
resulting in novel events
TDP-43 
LOF
TDP-43 
GOF
TDP-43 
normal 
function
TDP-43
Figure 4. Diagram illustrating the effect of TDP-43 loss and gain of function on events where it acts to inhibit exon inclusion.
TDP-43 has been shown to repress the inclusion of exons by binding to the pre-mRNA sequence of exons or to the downstream introns. In normal conditions, TDP-43 binding
contributes to fully repress the inclusion of exons to mature transcripts (top left); it contributes to regulate the inclusion of alternatively spliced exons (top centre); and it also
binds to exons and their downstream introns without an effect on exon exclusion (top right). TDP-43 LOF alters the balance of TDP-43 regulated alternative splicing and
induces the de-repression of normally excluded exons, cryptic exons (bottom left). TDP-43 GOF affects TDP-43 regulated alternative splicing in the opposite manner and also
induces the exclusions of otherwise normally constitutive exons, cryptic exons (bottom right).
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with ALS/FTD, we asked whether the molecular phenomena we
identified are induced by other LCD disease-causing mutations.
Thus, we generated a novel knock-in (KI) model via CRISPR/Cas9
genome editing carrying a Q331K mutation (Fig 7A) and we
assessed splicing effects by performing RT–PCR on primary cells
and adult spinal cord from these mice. As identified in LCDmut, we
confirmed a gain of splicing function in Q331K mice leading to
increased exon skipping in the CFTR minigene and in endogenous
Sortilin 1 and Eif4h and increased exon inclusion in Kcnip2 (Fig 7B
and C). Furthermore, we were able to confirm that Q331K also
induces the presence of SEs in Ube3c, Pex16 and Pacrgl (Fig 7D).
An important difference between the SEs and CEs is the signifi-
cantly higher conservation of SEs across species (Fig 5C), leading to
the question of whether these events are present in patients carrying
ALS-causing TARDBP mutations. We used fibroblasts from four dif-
ferent ALS patients carrying the TARDBP G298S and A382T patho-
genic variants (Appendix Table S6) to investigate whether SEs occur
in patient cells. We tested the seven SEs we had validated in our
mice and found two to be present and significantly changed in
patient-derived mutant fibroblasts when compared to controls
(Fig 7E and Appendix Fig S10). Overall, these findings in a novel
knock-in mouse line and in patient-derived cells support the finding
that splicing GOF is induced by ALS-causing mutations, although
further studies will be necessary to assess how widespread the GOF
induced by ALS-causing mutations is.
Discussion
Both TDP-43 gain and loss of function have been proposed as possi-
ble crucial mechanisms in the pathogenesis of ALS, a devastating
incurable neurodegenerative disorder, and both reduced TDP-43
expression and TDP-43 overexpression have detrimental effects in
mice (Arnold et al, 2013; Yang et al, 2014).
Here, we present novel mouse lines with point mutations within
endogenous Tardbp. As TDP-43 is very tightly autoregulated, and
in transgenic mice, even small changes in WT TDP-43 levels
induce vast LOF/GOF transcriptome alterations, our mice provide
the unique possibility of investigating the effect of mutations on
TDP-43 function in absence of confounding effects due to over-
expression.
We show with a well-established splicing assay and RNA-seq
that the RRM2 mutation leads to a dose-dependent loss of TDP-43
function, whereas the LCDmut leads to a gain of function.
The LOF effect of RRM2mut was expected, because the mutation
reduces TDP-43 RNA binding capacity; thus, this mouse model
C D E
A B
Figure 5. SEs are induced by TDP-43 RNA binding and determine transcript dysregulation.
A, B RNA maps show binding distribution of TDP-43 iCLIP clusters (positive and negative values on y-axis for increased and decreased ΔPSI respectively) in CEs in
RRM2mut (A) and SEs in LCDmut (B); red and blue indicate when cluster coverage is increased above background set of non-regulated cassette exons (grey). Below,
binding sites for the top 20 most significant CEs (A) and SEs (B) are plotted.
C Per-exon mean PhyloP conservation scores of RRM2mut CEs, LCDmut SEs and all annotated mouse exons. Scores are displayed as violin plots to show the full
distribution of data points with overlaid boxplots to show the median and quartiles. Notches represent the 95% confidence interval of the median, and whiskers
represent the minimum and maximum values that fall within 1.5 times the interquartile range. Outliers are plotted as black dots.
D The relationship between splicing status and differential expression in LCDmut. Significantly downregulated genes (FDR < 0.1) are enriched in SEs compared to
genes expressed at a similar level (P = 1.19e-6), as well as non-skiptic cassette exons (P = 6.16e-5). Upregulated genes are mildly enriched in non-skiptic cassette
exons (P = 0.029) but not in SEs (P = 0.88). All P-values generated from a binomial test.
E Damaging and unstable changes are more frequent in downregulated SEs (53.8%) versus other SEs (17.6%). *P = 0.034; chi-squared test.
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provides a novel tool to study chronic LOF in vivo and notably, in
contrast to homozygous TDP-43 null mice, which do not survive
beyond embryonic day 6 (E6.5; Kraemer et al, 2010; Sephton et al,
2010; Wu et al, 2010; Ricketts et al, 2014), RRM2mut embryos
survived to at least E18.5, allowing us to study embryonic tissue
and primary cell cultures.
Conversely, the splicing GOF effect produced by LCDmut is unex-
pected and, although GOF effects had been previously described in
transgenic models where TDP-43 is overexpressed, the physiological
setting of the mutations in these mice shows for the first time that
C-terminal TDP-43 mutations result in a splicing GOF.
Compound heterozygous animals from intercrosses between the
RRM2 and LCDmut strains show a partially rescued mouse embry-
onic lethality and a rescue of the majority of splicing changes
demonstrating that the LOF and GOF compensate each other in vivo.
The partial rescue of the lethality phenotype may reflect the non-
symmetry of the LOF/GOF changes.
Studying primary cells and tissue from our two models side by
side has allowed us to dissect LOF and GOF and to identify common
targets and specific features of the two processes. Genome-wide
analysis identified splicing targets that are affected in opposing
directions by RRM2mut and LCDmut. Interestingly, also unique
splicing events occur within each mutant.
We have identified that GOF induces the skipping of normally
constitutively expressed exons, here named skiptic exons. These
events are induced by the TDP-43-dependent splicing GOF mecha-
nism we describe, but occur within a set of genes previously
unknown to be regulated by TDP-43. Intriguingly, these events
appear to mirror a previously described phenomenon, whereby
TDP-43 LOF induces the inclusion of cryptic exons. Importantly,
combining our RNA-seq and iCLIP data, we show that the TDP-43
binding pattern surrounding CEs and SEs is very similar, supporting
a role for TDP-43 binding in regulating both events. TDP-43 is
involved in the exclusion of these exons; therefore, GOF determines
excessive exclusion, whilst LOF de-represses exons that are
normally not included (Fig 4). Although TDP-43 RNA binding likely
mediates the splicing GOF, it is unclear what determines the GOF
and whether changes in protein–protein interactions caused by the
C-terminal mutations could contribute to the GOF. This is a possibil-
ity that will require further study. Whilst TDP-43 binds to thousands
A B
C D E
Figure 6. LCDmut develops a neuromuscular and neurodegenerative phenotype.
A LCDmut homozygous female mice show significant 30% grip strength deficit at 2 years, whilst no change is present at 7 months. P = 0.829 (7 months) and
***P < 0.0001 (2 years), Mann–Whitney test. Mean and SEM plotted; N = 8–10, as plotted.
B TA muscle strength is decreased in 2-year-old LCDmut mice; representative traces are shown, x-axis, time; y-axis, force (top) and tetanic force from 5 LCDmut
(64.5 g  26.8 SD) and WT (104.4 g  26.1 SD) female mice are plotted (bottom). *P = 0.0113, Mann–Whitney test N = 8–10, as plotted.
C Surviving motor units for the EDL muscle are reduced in 2-year-old LCDmut (24.7  2.8 SD) compared with WT (28.9  1.9 SD); representative traces where each
twitch trace recording is a single motor unit (left). *P = 0.0057, Mann–Whitney test. N = 9–10, as plotted.
D Counts of MNs from L4–L5 show a significant reduction (28% reduction; *P = 0.0159, Mann–Whitney test, mean and SD plotted) N = 4–5, as plotted.
E LCDmut mice show p62 pathology in the spinal cord ventral horns at > 18 months. Scale bar indicates 10 lm.
Data information: Two-tailed Mann–Whitney t-test P-values are plotted as: *P < 0.05; ***P < 0.001.
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of constitutive exons throughout the transcriptome, only 44
undergo skipping in the presence of LCDmut induced GOF; this is
likely due to the cooperative nature of splicing and that TDP-43 is
only one of many factors involved in the regulation of the inclu-
sion/exclusion of the thousands of exons it binds to (Mohagheghi
et al, 2016).
C
D
BA
E
Figure 7. TDP-43 splicing GOF and skiptic exons are present in a novel knock-in mouse model and in patient-derived cells.
A Diagram illustrating location of ALS-causative mutations in Tardbp (Q331K, mouse knock-in) and TARDBP (G298S and A382T, patient-derived fibroblasts).
B Agarose gel and quantification of CFTR minigene splicing assay performed on MEFs from Tardbp Q331K homozygous (HOM, N = 3), heterozygous (HET, N = 3) and
littermate (WT, N = 3) controls show a decrease in exon inclusion in mutant vs. WT controls (P = 0.0003). Middle band represents the activation of a cryptic site in
the minigene.
C PSI quantification from agarose gels shows significant Sortilin 1 (P < 0.0001) splicing changes in MEFs from Q331K mice (similarly to LCDmut in Fig 1B) and
significant Eif4h (P = 0.0290) and Kcnip2 (P = 0.0053) GOF changes in 3-month Q331K spinal cord (WT N = 3, Het N = 2–3, HOM N = 3).
D Significant increase and quantification of Ube3c (P = 0.0004), Pex16 (P = 0.0010) and Pacrgl (P = 0.0086) SEs in Q331K mouse spinal cord (WT N = 3, Het N = 2–3,
HOM N = 3).
E PLOD1 and SLC6A6 SEs are present and significantly increased in fibroblasts derived ALS patients carrying TARDBP pathogenic mutations. PLOD1 (t-test; P = 0.01713);
SLC6A6 (t-test; P = 0.02224); N = 4.
Data information: Representative gels (top) include TARDBP G298S for SLC6A6 and TARDBP A382T for PLOD1; quantification (bottom)—ratio between SE and the exon
inclusion bands, after normalizing the mean of healthy controls to 100%, is used instead of PSI, as amplification was performed using a three primer PCR. For (B, C and
D), P-value from ANOVA is indicated in legend and Bonferroni multiple comparison test P-values are plotted as: *P < 0.05; **P < 0.01; ***P < 0.001. Mean and SEM are
plotted.
Source data are available online for this figure.
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TDP-43 acts to regulate alternative splicing, but critically, here
we uncover how GOF and LOF have an effect on exons that are
usually not alternatively regulated, but are instead constitutively
included or excluded. Thus, CEs and SEs are not a novel splicing
mechanism, but the effect of LOF and GOF, respectively, on a subset
of constitutively included and excluded exons. This phenomenon is
important as it highlights how TDP-43 GOF and LOF determine
alterations in distinct subsets of genes (Fig 4).
We find downregulation of the overall expression of genes
harbouring skiptic exons in LCDmut mice, showing that these novel
events lead to changes in expression levels. Interestingly, 7/44 iden-
tified SEs are within genes involved in the ubiquitin proteasome
pathway, including five E3 Ubiquitin ligases: Herc2, Ube3c, Wwp1,
Ttc3 and Wsb1. Overall, these data raise the question of whether
these events have the potential to alter CNS proteostasis, a central
mechanism involved in neurodegeneration (Ling et al, 2013).
In vivo, LCDmut mice develop progressive motor deficits, muscle
weakness, reduced motor unit numbers and MN loss accompanied by
p62- and ubiquitin-positive ventral horn inclusions. By 24 months,
the mice do not develop paralysis or show premature death, which
are typical features of ALS; instead, the progressive phenotype they
develop resembles the initial stages of disease. This is consistent with
other ALS models, as overexpression of ALS proteins induces rapid
severe phenotypes in transgenic mice (Gurney et al, 1994; Mitchell
et al, 2013), whilst mutations in endogenous Sod1 and Fus show
slower milder neuromuscular phenotypes (Joyce et al, 2014; Devoy
et al, 2017; Scekic-Zahirovic et al, 2017).
The progressive neuromuscular phenotype accompanied by MN
loss supports the relevance to disease of the LCDmut mice, that
carry a mutation which shares similarities in vitro with the ALS-
causing Q331K mutation, but has not yet been identified in ALS
patients. Here, we use the Q331K knock-in strain, which is currently
being aged and fully characterised, to show that splicing GOF is also
present in this ALS-causing C-terminal TDP-43 mutant. The effect
observed in Q331K was significant, but smaller than in LCDmut,
possibly due to the younger age of the analysed mice or the different
genetic background. Lastly, we were able to move from a classic
investigation of mechanism in CNS of mouse models, to examining
the same phenomena in patient-derived cells. We validated two of
the skiptic exons in fibroblasts derived from patients carrying
TARDBP ALS-causative mutations—these results warrant more
comprehensive transcriptomic studies in patient-derived material,
which are currently lacking for TARDBP ALS mutations.
Importantly, the motor phenotype in homozygous LCDmut mice
develops without TDP-43 nuclear depletion, TDP-43 inclusions or
features of TDP-43 LOF, such as the inclusion of cryptic exons or
downregulation of long intron genes, showing that these phenom-
ena are not necessary for the initial stages of neurodegeneration, as
also demonstrated by others (Arnold et al, 2013).
An abnormal upregulation of TARDBP has been shown in human
TDP-43-ALS post-mortem end-stage brain, likely due to the absence
of nuclear TDP-43 protein, and a vicious cycle of increased expres-
sion has been proposed to play a role in disease (Koyama et al,
2016). Here, unexpectedly, we found an imbalance in the autoregu-
lation and the upregulation of Tardbp levels in LCDmut, throughout
life, although protein levels were not significantly increased. It is
important to note that in Tardbp heterozygous null mice, changes in
TDP-43-dependent splicing occur in the absence of detectable
TDP-43 protein changes (Ricketts et al, 2014), and therefore,
whether in LCDmut mice a subtle chronic increase in TDP-43 levels,
below the detection threshold from Western blotting, could contri-
bute to the observed GOF, will need to be investigated.
Intriguingly, the fact that both gain and loss of function induce
Tardbp upregulation suggests the autoregulation imbalance may be
a common process throughout disease and potentially represents a
target for disease-modifying interventions. Importantly, our data
show that TDP-43 GOF and LOF do not simply act on the same set of
genes; rather, both are characterised by specific effects on gene regu-
lation, producing a unique transcriptomic signature that may play
distinct roles at different stages of disease pathogenesis. Indeed,
whilst LOF likely plays a role at disease end stage, here we show that
GOF is sufficient to initiate the neurodegenerative process.
In summary by working with mouse models with endogenous
mutations in key TDP-43 domains and with patient-derived human
fibroblasts, we separate GOF and LOF mechanisms and their effects,
we provide a novel mouse model of ALS and identify an entirely
unsuspected GOF acting on splicing of conserved constitutive exons.
Finally, we show that, at least in this model, LOF is not necessary
for initiating the neurodegenerative processes, whilst highlighting
that the occurrence of splicing GOF is associated with the early
stages of disease.
Materials and Methods
Mouse lines
The Tardbp RRM2mut and LCDmut lines were derived from the
RIKEN BioResource Center and are available as BRC no. GD000108
and GD000110 from RIKEN BioResource Center, respectively.
The Tardbp Q331K line was generated in this study and is avail-
able upon request.
Screening, identification and generation of ENU mouse lines
The RIKEN and MRC Harwell ENU-DNA archives were screened for
coding mutations within Tardbp. The mutant lines were screened
and established from both ENU mutant mouse libraries as previously
described (Coghill et al, 2002; Sakuraba et al, 2005). Briefly, we
screened the PCR-amplified fragments from a total of < 10,000 G1
individuals DNA samples by heteroduplex detection system. The G1
genomic DNA samples that exhibited the heteroduplex signals were
subjected to Sanger sequencing to identify the ENU-induced muta-
tions. We found seven Tardbp missense mutations: T4C, A42C,
N45S, K160R, F210I, N312S and M323K. We selected F210I (RRM2-
mut) and M323K (LCDmut) for further analysis, which were initially
on a hybrid DBA/2JxC57BL/6J background. Mice were rederived via
in vitro fertilisation (IVF) using frozen F1 sperm at RIKEN and main-
tained on C57BL/6J and DBA/2J backgrounds at MRC Harwell.
Mouse housing, maintenance, genotyping and grip
strength analysis
All animals were housed and maintained in the Mary Lyon Centre,
MRC Harwell, under specific opportunistic pathogen-free (SOPF)
conditions, in individually ventilated cages adhering to
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environmental conditions as outlined in the Home Office Code of
Practice. All animal studies were licensed by the Home Office under
the Animals (Scientific Procedures) Act 1986 Amendment Regula-
tions 2012 (SI 4 2012/3039), UK, and additionally approved by the
Institutional Ethical Review Committee. Mice were euthanised by
Home Office Schedule 1 methods.
Initial genotyping for the Q331K mutation was performed as
follows: genomic DNA from F0 and F1 animals was extracted
from ear clip biopsies using DNA Extract All Reagents Kit
(Applied Biosystems). The targeted region was PCR-amplified using
high-fidelity Expand Long Range dNTPack (Roche) and genotyping
primers Geno_Tardbp_F1/R1. PCR products were further purified
using gel extraction kit (Qiagen) and analysed by Sanger sequenc-
ing. PCR product amplified from DNA obtained from F0s that
showed the correct point mutation (C>A inducing Q331K) was sub-
cloned using Zero-Blunt PCR cloning Kit (Invitrogen), and 12 clones
were analysed by Sanger sequencing.
A grip strength meter (BioSeb) was used to measure muscle
strength. Total limb (fore and hind) were measured twice with an
average value recorded, as previously (Ricketts et al, 2014).
Mouse embryonic fibroblasts (MEFs) and silencing of TDP-43
Mouse embryonic fibroblasts were derived following established
protocols from E14.5 embryos derived from intercrosses to obtain
all genotypes within one generation, allowing to use littermates as
controls. Primary cells were not tested for mycoplasma. In order to
obtain TDP-43 knockdown in MEFs, we used shRNA from the GIPZ
Lentiviral shRNA library (GE Dharmacon) with the following
sequence shared between mouse Tardbp and human TARDBP
(TGGATGAGACAGATGCTTC) in parallel with scramble control. In
order to improve the percentage of MEFs expressing shRNA, 3 days
after transfection, MEFs underwent 3-day treatment with puromycin
at 4 lg/ml and 3 days at 2 lg/ml before being harvested in RIPA
buffer for protein analysis and Trizol for RNA extraction. Tardbp
levels were validated using Tardbp FAM TaqMan probes along with
Gapdh and Actb VIC probes in separate reactions.
CFTR minigene assay
Electroporation was used to transfect the CFTR minigene construct
(Buratti et al, 2007) into MEFs of the different Tardbp genotypes.
Briefly, an Amaxa system (Lonza) was used following manufac-
turer’s instructions. After 24 h, MEFs were harvested and cell pellets
snap-frozen. For this and any other validation of any splicing event,
RNA was extracted following standard procedures via Trizol (Life
Technologies) or columns (Qiagen), and cDNA produced via RT–
PCR following manufacturer’s instructions (Applied Biosystems,
QuantaBio). CFTR exon inclusion was assessed via semiquantitative
RT–PCR using primers specific against the minigene construct.
Electrophoretic mobility shift assay (EMSA)
Mouse TDP-43 WT and the different mutations were expressed in
Escherichia coli with a GST tag that was used to purify the different
recombinant proteins. Different concentrations of recombinant
proteins (0.25, 0.5, 1, 2 lg) or UG6 repeats were used for different
assays. The EMSA gel (5% acrylamide) was loaded with the
recombinant protein in binding buffer together with c32P labelled RNA
(UG6 repeats or Tardbp CLIP sequence). After the run was completed,
the gel was dried (583 Gel Dryer Bio-Rad) and visualised using
X-OMAT film or autoradiographic XAR film (F5763 Sigma/Kodak).
RNA isolation, quality control, RT–PCR and RT–qPCR
For validation of splicing events from different sources, RNA was
extracted from MEFs, embryonic E18.5 head or adult spinal cord.
RNA quality was determined by RNA Integrity Number (RIN)
measured using RNA ScreenTape and reagents (Agilent) on the 2200
Tapestation System (Agilent). RT–PCR protocol was conducted follow-
ing manufacturer’s instructions (Thermo, QuantaBio, Applied Biosys-
tems). PCR for splicing events was conducted using 2X PCR Master
Mix (Thermo) with specific primers spanning the differentially
expressed exon (RRM2mut cryptic n = 4, LCDmut skiptic n = 4,
Q331K splicing/skiptic n = 3). Products were electrophoresed on
agarose gels with ethidium bromide (Sigma) or using D1000 Screen-
Tape and reagents (Agilent) on the 2200 Tapestation system (Agilent).
Results were analysed using PSI, calculated dividing the intensity of
the exon inclusion band by the sum of both exon inclusion and exon
exclusion bands. When analysing SEs in human fibroblasts, as a
combination of three primers was used, we did not calculate PSI, but
calculated the ratio between SE band and the exon inclusion band and
expressed results after normalizing the mean of healthy controls to
100%. Primer sequences are available upon request.
RNA-sequencing
RNA-seq was performed using polyA libraries as previously
described (Wang et al, 2012; Joyce et al, 2016) and all RNA-sequen-
cing generated for this study, along with read-length and average
uniquely mapped reads are summarised in the table below. All
mutants were compared to wild-type littermates. N refers to the
number per genotype (control, heterozygous and homozygous).
All sequencing data are deposited in the NCBI Sequence Read
Archive (reference: SRP133158).
iCLIP
iCLIP was performed as detailed by Ko¨nig et al (2010). Dissected
forebrain (RRM2mut) or adult brain (LCDmut) were homogenised
in phosphate-buffered saline (PBS) and UV-crosslinked 4× at 100
mJ/cm2 at a wavelength of 254 nm (RRM2mut n = 2, LCDmut
n = 1–2). Protein concentrations were normalised using the DC
Protein Assay (Bio-Rad), and the lysate was then sonicated for 30 s
×10 times. Lysates were then treated with 0.1 U/ll RNase I
(Thermo) and Turbo DNase (Thermo). Anti-TDP-43 antibody
(Sigma) was conjugated to Dynabeads Protein A (Thermo) and used
to immunoprecipitate TDP-43 from the tissue lysate. The 30 ends of
attached transcripts were then dephosphorylated using T4 PNK
(NEB) and the pre-adenylated L3-App adaptor ligated using RNA
ligase (NEB). The 50 end of transcripts were labelled with radioiso-
tope ATP[c32P] using T4 PNK. The labelled complexes were then
resolved on NuPAGE 4–12% Bis-Tris gels (Invitrogen), transferred
to nitrocellulose membrane and exposed to Fuji film. The protein–
RNA complexes corresponding to TDP-43 size of 43 kDa and above
were isolated, and the protein was digested with proteinase
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K (Sigma). RNA fragments were reverse-transcribed using Super-
Script III (Invitrogen) and size-resolved on Novex 6% TBE-urea gels
(Invitrogen). Bands of size 75–95 nt and 95–200 nt were excised,
further purified, circularised using Circligase (Epicentre) and digested
with BamHI. cDNA fragments were amplified by PCR and further
purified with Ampure XP beads (Beckman Coulter). The iCLIP
libraries were quantified using the D1000 ScreenTape and reagents
(Agilent) on the 2200 Tapestation System (Agilent) and sequenced
using the standard Illumina protocol for 50-bp single-end sequencing
(Huppertz et al, 2014).
Immunohistochemistry
For analysis of spinal cord pathology, 1- and 2-year-old WT,
LCDmut HET and HOM mice were perfused with saline followed by
4% PFA. The spinal cord was stored in formalin and then embedded
in paraffin wax. 4-lm transverse sections were taken from the
lumbar regions of the spinal cord. Staining for p62 (1:250, Abcam),
TDP-43 (1:500, Novus Biologicals) and ubiquitin (1:5,000, Santa
Cruz) was conducted using a Ventana immunohistochemical
staining machine (Ventana). Following staining with the appro-
priate secondary antibodies, the sections were developed with
3,3-diaminobenzidine. All experiments were carried out using a
positive [human frontotemporal dementia (FTD) cortex] and
negative control.
Immunoblot
Spinal cords from 2-year-old LCDmut HOM mice were homogenised
in RIPA buffer with protease inhibitors. The homogenate was resolved
using Western blot using NuPAGE 4–12% Bis-Tris gels (Invitrogen)
using anti-TDP-43 (Proteintech). Quantification of the results was
conducted on the Odyssey infrared imaging system (Li-Cor).
Turbidity assay
Briefly, turbidity measurements were obtained on WT and mutant
TDP-43 C-terminal fragments (267–414) thawed from frozen stock,
desalted into 20 mM MES (pH 6.1) and diluted to 20 lM in a 100 ll
final volume in 20 mM MES supplemented with 0–500 mM NaCl
(Conicella et al, 2016). Turbidity at room temperature was quanti-
fied by measuring the optical density at 600 nm wavelength light at
5-min intervals over a 12-h time period. All measurements were
recorded in triplicate in sealed 96-well clear bottom plates.
Motor neuron survival
Mice were terminally anaesthetised with 4.5% chlorohydrate (1 ml/
100 g of body weight), transcardially perfused with 4% PFA and the
lumbar region of the spinal cord removed, post-fixed in 4% PFA and
cryopreserved in 30% sucrose. Serial 20-lm transverse sections were
cut on a cryostat, stained with gallocyanin, a Nissl stain, and the
number of positively stained motor neurons in the sciatic motor pool
of every third section between the L4 and L5 levels of the spinal cord
was counted, as previously described (Joyce et al, 2016). Only large,
polygonal neurons with a clearly identifiable nucleus and nucleolus
were included in counts. This protocol avoids the possibility of
counting the same cells twice in consecutive sections. A total of 40
sections were examined per spinal cord, and at least five female mice
were analysed from each experimental group.
Physiology analysis
Muscle force and motor unit number female WT and LCDmut litter-
mates (N = 5) were examined at 24 months of age, as described
previously (Joyce et al, 2016). In summary, in anesthetised mice
(4.5% chlorohydrate, 1 ml/100 g of body weight), the distal tendons
of the tibialis anterior (TA) and extensor digitorum longus (EDL)
muscles in both hindlimbs attached to isometric force transducers
(Dynamometer UFI Devices, Welwyn Garden City, UK), and the
sciatic nerve exposed and sectioned. Squarewave pulses of 0.02 ms
duration at supra-maximal intensity were used to stimulate the nerve
and elicit TA or EDL isometric contractions. Trains of stimuli at
frequencies of 40, 80 and 100 Hz were used and were measured
using Scope software. Motor unit numbers innervating the EDL was
determined by using stimuli of increasing intensity, resulting in incre-
mental increases in twitch tension due to successive recruitment of
motor axons. The number of increments was counted giving an esti-
mate of the number of functional motor units present in EDL muscle.
Generation of Tardbp Q331K knock-in mice
The founder mutant Q331K mice were produced and characterised
as per Mianne´ et al (2017). Specifically, the mutants were generated
through C57BL/6J zygote pronuclear injection of CRISPR reagents,
including the Cas9 mRNA, a sgRNA and a PAGE-purified ssODN
donor template at 100, 50 and 50 ng/ll, respectively. Pups were
genotyped by genomic DNA PCR amplification and Sanger sequenc-
ing of the targeted sequence. The mutant harbouring the intended
nucleotide modification (C>A inducing Q331K) was then mated to a
wild-type (WT) counterpart in order to assess germline transmission
of the Q331K mutated allele. sgRNA was selected using online design
tools in order to cut as close as possible to the targeted nucleotide
change, having as few potential off-targets and having the minimal
total number of potential off-targets (especially on the targeted chro-
mosome 4). The ssODN donor oligo was ordered as PAGE-purified
UltramerTM DNA oligo (IDT). The targeted nucleotide change
disrupting the recognition site of the sgRNA selected, no additional
modification was added to the ssODN donor oligo. Single-guide
RNAs were synthesised from a plasmid containing the T7 promoter
using MEGAshortscript kit (Ambion) following manufacturer’s
instructions and purified using MEGAclear kit (Ambion). RNA qual-
ity was assessed using a NanoDrop (Thermo Scientific) and by elec-
trophoresis on 2% agarose gels containing ethidium bromide (Fisher
Scientific). Cas9 mRNA was synthesised in-house from a plasmid
containing mammalian codon optimised Cas9 sequence under T7
promoter. The plasmid was linearised and phenol–chloroform puri-
fied; mRNA was synthesised using Message Max T7 Arca Capped
Message Transcription Kit (Cellscript), polyadenylated using poly(A)
polymerase Tailing Kit (Epicentre) and purified using MEGAclear kit
(Ambion). mRNA quality was assessed using a NanoDrop (Thermo
Scientific) and by electrophoresis on 2% agarose gel containing
ethidium bromide (Fisher Scientific).
Pronuclear microinjection was performed as per Gardiner &
Teboul (2009), employing a FemtojJet (Eppendorf) and C57BL/6J
embryos. Specifically, injection pressure (Pi) was set between 100
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and 700 hPa, depending on needle opening; injection time (Ti) was
set at 0.5 s and the compensation pressure (PC) was set at 10 hPa.
Microinjection buffer (MIB; 10 mM Tris–HCl, 0.1 mM EDTA,
100 mM NaCl, pH 7.5) was prepared and filtered through 2-nm filter
and autoclaved. Cas9 mRNA, sgRNA and ssODN were diluted and
mixed in MIB to the working concentrations of 100, 50 and 50 ng/
ll, respectively. Injected embryos were re-implanted in CD1 pseudo-
pregnant females. Host females were allowed to litter and rear F0s.
All sequences used to generate and characterise the mutants are
the following: sgRNA: GGCAGCGTTGCAGAGCAGTT GGG; ssODN
donor (targeted nucleotide change in bold and underlined):
CCCGACTGGTTCTGCTGGCTGGCTAACATGCCCATCATACCCCAAC
TGCTCTTCAACGCTGCCTGAGCCGCAGCCATCATCGCTGGGTTAAT
GCTAAAAGCACCAAAGTTCATCCCTCCACCCATATTACCACCCTGG
TTATTTCCCAAGCCAGCTCCACCCCCTCTACTGTTACCAAACCCAC
CCTGATTCCCAAAGCC.
Human fibroblasts
Fibroblasts were obtained from a 4-mm skin punch biopsy taken
following informed consent under local anaesthetic. Biopsies were
dissected into ~1-mm pieces and cultured in DMEM, 10% FBS, 1%
L-glutamine until fibroblasts grew out from the explants. When con-
fluent, fibroblasts were detached, further expanded and underwent
cryopreservation. They were maintained in DMEM with 10% FBS
and 1% penicillin/streptomycin under standard culture conditions.
Clinical information and genetic changes are summarised in
Appendix Table S6.
Transcriptomics analysis methods are described in detail in
Appendix Supplementary Materials and Methods.
Expanded View for this article is available online.
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